Omalizumab (anti-IgE)

Omalizumab is a monoclonal antibody that blocks binding of IgE to high-affinity receptors on mast cells.

•  It is adjunctive therapy in patients aged 12 years or older with sensitivity to relevant allergens and who require step 5 or 6 care for severe asthma.

• Patients requiring omalizumab therapy should be seen regularly by an asthma specialist.
• Physicians who administer omalizumab should be prepared to treat any anaphylaxis that may occur.